Source:
The Mylan plant in Morgantown, West Virginia willl restart production of hydroxychloroquine this week.
The drug was touted by researchers, doctors and President Trump in the treatment of the COVID-19 virus.
Generic Drug Company Teva in Israel is also mass-producing the drug to save lives.
The Dominion Post reported:
Mylan’s Morgantown plant is restarting production of an anti-malaria medication that is under study as a potential treatment for the COVID-19 virus.
The drug is hydroxychloroquine sulfate; the tablets are approved by the U.S. Food and Drug Administration for the treatment of malaria, lupus erythematosus and rheumatoid arthritis.
President Trump on Thursday touted its cousin, chloroquine, as a potential treatment and mistakenly said it has been FDA approved for COVID-19.
Mylan clarified, “Although the product is not currently approved for use in the treatment of COVID-19, it is listed by the World Health Organization as a drug under investigation for efficacy against the coronavirus.”
The drug had been in short supply earlier in March, according to news reports, but Mylan and another generic drug firm, Israel-based Teva, are both ramping up production.
